• The University of Western Australia (M504), 35 Stirling Highway,

    6009 Perth

    Australia

  • Source: Scopus
  • Calculated using citation counts from Scopus for publications in the UWA Profiles and Research Repository
If you made any changes in Pure these will be visible here soon.

Personal profile

Biography

Daniel R. Knight PhD UWA, BSc. Hons UCL, MASM

NHMRC Peter Doherty Early Career Fellow | Biosecurity and One Health Research Centre, Harry Butler Institute, Murdoch University

Adjunct Research Fellow | Marshall Centre for Infectious Diseases Research and Training, School of Biomedical Sciences, University of Western Australia

Office and Lab: Riley Laboratory, J Block, PathWest Laboratory Medicine, QEII Medical Centre, Monash Avenue, Nedlands WA 6009

 

About me

I am an NHMRC Early Career Fellow and expert in evolutionary and One Health aspects of infectious diseases epidemiology. I lead a program of research aimed at better understanding the epidemiology of Clostridium difficile Infection (CDI), one of the most important healthcare-associated infections and One Health issues in the developed world.

Using state-of-the-art microbial genomics, my team studies the genetic factors contributing to the emergence, evolution and spread of C. difficile in humans, animals and their shared environment. This work is at the forefront of the global efforts to better understand C. difficile evolution and challenges the long-held paradigm that CDI is exclusively a healthcare-associated infection, with implications for improved diagnostics, surveillance and treatment of CDI.

 

Career highlights

  • Chief Investigator funding since 2018: $525,000 AUD 
  • Co-investigator funding since 2018: $251,000 AUD
  • Peer-reviewed papers: 59 (h-index 22; 1590+ citations)
  • Recipient of the 2020 Jim Pittard Early Career Award and 2021 Raine Research Prize
  • Associate Editor, Anaerobe
  • Treasurer, Australian Society for Microbiology (WA Branch)

 

Competitive grants

  • Tai SA, Riley TV, Knight DR. Conquer Cystic Fibrosis Project Grant, 2022-2024. “Surveillance, genomic epidemiology and antimicrobial susceptibility of clinically important pathogens in patients with cystic fibrosis and bronchiectasis in Western Australia”. Conquer Cystic Fibrosis Ltd., $251,109.
  • Knight DR. Raine Priming Grant, 2019-2020. ‘One Health: A new paradigm for studying evolution and transmission in Clostridium difficile’. Raine Medical Research Foundation(RPG002-19), $199,950.
  • Knight DR. Peter Doherty Early Career Biomedical Research Fellowship, 2018-2021. “A One Health approach to assessing the threat of Clostridium difficile to Australia’s biosecurity: a genomic investigation of human, animal and environmental isolates”. National Health and Medical Research Council(APP1138257), $327,193.

 

Major awards

  • Knight DR. Recipient of the 2021 Raine Research Prize (Raine Medical Research Foundation). Awarded to an ECR in WA with the most outstanding scientific paper that seeks to better understand the nature, origin, and cause of human diseases, and their prevention and treatment. 
  • Knight DR. Recipient of the 2020 ASM Jim Pittard Early Career Award (Australian Society for Microbiology) in recognition of early-career research excellence and distinguished contribution to Australian research in Microbiology.

 

Other awards, prizes and scholarships

  • Knight DR. 2018 International One Health Fellowship, The One Health Platform. June 2018, Saskatoon, Canada ($3,600).
  • Knight DR. Travel Award, 19th Annual Scientific Meeting of the Australian Society for Antimicrobials (ASA). Feb 2018, Brisbane, Queensland, Australia. ($2,500).
  • Knight DR. Best ‘One Health’ Presentation, 10th International Conference on the Molecular Biology and Pathogenesis of the Clostridia (CLOSTPATH). Aug 2017, Ann Arbor, Michigan, USA. (Book Prize).
  • Knight DR. Trainee Travel Award, 10th International Conference on the Molecular Biology and Pathogenesis of the Clostridia (CLOSTPATH). Aug 2017, Ann Arbor, Michigan, USA ($815).
  • Knight DR. ASM Nancy Millis Student Award, Australian Society for Microbiology (ASM), July 2016 ($470).
  • Knight DR. Wellcome Trust Advanced Courses Scholarship and Postgraduate Travel Award, April 2015. Wellcome Trust, European Bioinformatics Institute and The University of Western Australia. ($3,170).
  • Knight DR. Australian Postgraduate Award, 2013-2017. Australian Federal Government. ($86,000).
  • Knight DR. Postgraduate Scholarship, 2013-2017. The University of Western Australia. ($63,000).

 

Refereed journal articles

2021

  • Imwattana K, Rodríguez C, Riley TV, Knight DR. 2021. A species-wide genetic atlas of antimicrobial resistance in Clostridioides difficile. Microb Genom [Accepted Sept 2021].
  • O’Grady KI, Riley TV, Knight DR. 2021. Complete genome assemblies of three highly prevalent, toxigenic Clostridioides difficile strains causing healthcare-associated infections in Australia. Microbiol Resour Announc 10:e00599-21 https://doi.org/10.1128/MRA.00599-21
  • Mahadari MK, Tague AJ, Putsathit P, Hutton ML, Hammer KA, Knight DR, Riley TV, Lyras D, Keller PA, Pyne SG. 2021. Cationic peptidomimetic amphiphiles having a N-aryl- or N-naphthyl-1,2,3-triazole core structure targeting Clostridioides (Clostridium) difficile: Synthesis, antibacterial evaluation and an in vivo C. difficile infection model. Antibiotics 10:913 https://doi.org/10.3390/antibiotics10080913
  • O’Grady KI, Knight DR, Riley TV. 2021. Antimicrobial resistance in Clostridioides difficileEur J Clin Microbiol Infect Dis [Accepted Jul 2021] https://doi.org/10.1007/s10096-021-04311-5
  • Knight DR, Imwattana K, Kullin B, Guerrero-Araya E, Paredes-Sabja D, Didelot X, Dingle KE, Eyre DW, Rodríguez C, and Riley TV. Major genetic discontinuity and novel toxigenic species in Clostridioides difficile taxonomy. eLife 10:e64325. https://doi.org/10.7554/eLife.64325
  • Putsathit P, Hong S, George N, Hemphill C, Huntington PG, Korman TM, Kotsanas D, Lahra M, McDougall R, McGlinchey A, Moore C, Nimmo G, Prendergast L, Robson J, Waring L, Wehrhahn MC, Weldhagen GF, Wilson R, Riley TV, Knight DR. 2021. Antimicrobial resistance surveillance of Clostridium difficile in Australia, 2015–2018. J Antimicrob Chemother  https://doi.org/10.1093/jac/dkab099
  • Imwattana K, Knight DR, Riley TV. 2021 Can sequencing improve the diagnosis and management of Clostridioides difficile infection? Expert Rev Mol Diagn 10.1080/14737159.2021.1915774
  • Imwattana K, Putsathit P, Knight DR, Kiratisin P, Riley TV. 2021 Molecular characterisation of, and antimicrobial resistance in, Clostridioides difficile from Thailand, 2017-2018. Microb Drug Res https://doi.org/10.1089/mdr.2020.0603 
2020
  • Hong S, Putsathit P, George N, Hemphill C, Huntington PG, Korman TM, Kotsanas D, Lahra M, McDougall R, Moore C, Nimmo G, Prendergast L, Robson J, Waring L, Wehrhahn MC, Weldhagen GF, Wilson R, Riley TV, Knight DR. Laboratory-based surveillance of Clostridium difficile infection in Australian healthcare and community settings, 2013–2018. J Clin Microbiol 58 (11) e01552-20 https://doi.org/10.1128/JCM.01552-20
  • Imwattana K, Kiratisin P, Riley TV, Knight DR. 2020. Genomic basis of antimicrobial resistance in non-toxigenic Clostridium difficile in Southeast Asia. Anaerobe 66:102083 https://doi.org/10.1016/j.anaerobe.2020.102290
  • Lim S‐C., Knight DR, Moono P, Foster NF, Riley TV. 2020. Clostridium difficile in soil conditioners, mulches and garden mixes with evidence of a clonal relationship with historical food and clinical isolates. Environ Microbiol Rep 12:672-680.  https://doi.org/10.1111/1758-2229.12889
  • Lim S-C , Riley TV, Knight DR. 2020. One Health: the global challenge of Clostridium difficile infection. Microbiol Aust 41:23-27. https://doi.org/10.1071/MA20007
  • Imwattana K, Knight DR, Kullin B, Collins DA, Putsathit P, Kiratisin P, Riley TV. 2019. Antimicrobial resistance in Clostridium difficile ribotype 017. Expert Rev Anti Infect Ther 18:17-25. https://doi.org/10.1080/14787210.2020.1701436

2019

  • Lim S-C, Knight DR, Riley TV. 2019. Clostridium difficile and One Health. Clin Microbiol Infect S1198-743X(19)30559-2. https://doi.org/10.1016/j.cmi.2019.10.023
  • Putsathit P, Neela VK, Joseph NMS, Oiu PT, Ngamwongsatit B, Knight DR, Riley TV. 2019. Molecular epidemiology of Clostridium difficile isolated from piglets. Vet Microbiol 237:108408https://doi.org/10.1016/j.vetmic.2019.108408
  • Androga GO, Knight DR, Hutton ML, Mileto SJ, James ML, Evans C, LyrasD, Chang BJ, Foster NF, Riley TV. 2019. In silico, in vitro and in vivo analysis of putative virulence factors identified in large clostridial toxin-negative, binary toxin-producing C. difficile strains. Anaerobe 60:102083. https://doi.org/10.1016/j.anaerobe.2019.102083
  • Hong S, Knight DR, Chang B, Carman RJ, Riley TV. 2019. Phenotypic characterisation of Clostridium difficile PCR ribotype 251, an emerging multi-locus sequence type clade 2 strain in Australia. Anaerobe 60:102066. https://doi.org/10.1016/j.anaerobe.2019.06.019
  • Knight DR, Riley TV. 2019. Genomic delineation of zoonotic origins of Clostridium difficileFront Public Health 7:164. https://doi.org/10.3389/fpubh.2019.00164
  • Imwattana K, Knight DR, Kullin B, Collins DA, Putsathit P, Kiratisin P, Riley TV. 2019. Clostridium difficile ribotype 017 – characterization, evolution and epidemiology of the dominant strain in Asia. Emerg Microbes Infect, 8:796-807. https://doi.org/10.1080/22221751.2019.1621670
  • Azimirad M, Gholami F, Yadegar A, Knight DR, Shamloei S, Aghdaei HA, Zali MR. 2019. Prevalence and characterization of Clostridium perfringens toxinotypes among patients with antibiotic-associated diarrhea in Iran. Sci Rep 9:7792. https://doi.org/10.1038/s41598-019-44281-5
  • Knight DR, Kullin B, Androga GO, Barbut F, Eckert C, Johnson S, Spigaglia P, Tateda K, Tsai PJ, Riley TV. 2019. Evolutionary and genomic insights into Clostridioides difficile sequence type 11: a diverse, zoonotic and antimicrobial resistant lineage of global One Health importance. mBio 10:e00446-19. https://doi.org/10.1128/mBio.00446-19
  • Hong S, Knight DR, Riley TV. 2019. The impact of antimicrobial resistance on induction, transmission and treatment of Clostridium difficile infection. Microbiol Aust 40:77-81. https://doi.org/10.1071/MA19022
  • Tague AJ, Putsathit P, Hutton ML, Hammer KA, Wales SM, Knight DR, Riley TV, Lyras D, Keller PA, Pyne SG. 2019. Cationic biaryl 1,2,3-triazolyl peptidomimetic amphiphiles targeting Clostridioides (Clostridium) difficile: synthesis, antibacterial evaluation and an in vivo C. difficile infection model. Eur J Med Chem 170:203-224. https://doi.org/10.1016/j.ejmech.2019.02.068
  • Tague AJ, Putsathit P, Hammer KA, Wales SM, Knight DR, Riley TV, Keller PA, Pyne SG. 2019. Cationic biaryl 1,2,3-triazolyl peptidomimetic amphiphiles: Synthesis, antibacterial evaluation and preliminary mechanism of action studies. Eur J Med Chem 168:386-404. https://doi.org/10.1016/j.ejmech.2019.02.013
  • Wehrhahn MC, Keighley C, Kurtovic J, Knight DR, Hong S, Hutton M, Lyras D, Wang Q, Leong R, Borody T, Edye M, Riley TV. 2019. A series of three cases of severe Clostridium difficile infection in Australia associated with a binary toxin producing clade 2 ribotype 251 strain. Anaerobe 55:117-123. https://doi.org/10.1016/j.anaerobe.2018.11.009
  • Roshan N, Riley TV, Knight DR, Steer JH, Hammer KA. 2019. Natural products show diverse mechanisms of action against C. difficileJ Appl Microbiol 126:468-479. https://doi.org/10.1111/jam.14152
2018
  • Roshan N, Riley TV, Knight DR, Hammer KA. 2018. Effect of natural products on the production and activity of Clostridium difficile toxins in vitro. Sci Rep 8:15735. https://doi.org/10.1038/s41598-018-33954-2
  • Androga GOKnight DR, Lim SC, Foster NF, Riley TV. 2018. Antimicrobial resistance in large clostridial toxin-negative, binary toxin-positive Clostridium difficile ribotypes. Anaerobe 54:55-60. Authors contributed equally to this work. https://doi.org/10.1016/j.anaerobe.2018.07.007
  • Lim S-C, Androga GO, Knight DR, Moono P, Foster NF, Riley TV. 2018. Antimicrobial susceptibility of Clostridium difficile isolated from food and environmental sources in Western Australia. Int J Antimicrob Agents 52: 411-415. https://doi.org/10.1016/j.ijantimicag.2018.05.013
  • Amy J, Bulach D, Knight DR, Riley TV, Johanesen P, Lyras D. 2018. Identification of large cryptic plasmids in Clostridioides (ClostridiumdifficilePlasmid 96-97:25-38. http://dx.doi.org/10.1016/j.plasmid.2018.04.001
  • Man NYT, Knight DR, Stewart SG, McKinley AJ, Riley TV, Hammer KA. 2018. Spectrum of antibacterial activity and mode of action of a novel tris-stilbene bacteriostatic compound. Sci Rep 8:6912. http://dx.doi.org/10.1038/s41598-018-25080-w

2017

  • McGovern AM, Androga GO, Knight DR, Watson MW, Elliott B, Foster NF, Chang BJ, Riley TV. Prevalence of binary toxin positive Clostridium difficile in diarrhoeal humans in the absence of epidemic ribotype 027. PLoS One 12:e0187658. http://dx.doi.org/10.1371/journal.pone.0187658
  • PutsathitP, Maneerattanaporn M, PiewngamP, Knight DR, Kiratisin P, Riley TV. Antimicrobial susceptibility of Clostridium difficile isolated in Thailand. Antimicrob Resist Infect Con 6:58. http://dx.doi.org/10.1186/s13756-017-0214-z
  • Knight DR, Squire MM, Collins DA, Riley TV. Genome analysis of Clostridium difficile PCR ribotype 014 lineage in Australian pigs and humans reveals a diverse genetic repertoire and signatures of long-range interspecies transmission. Front Microbiol 7:2138. http://dx.doi.org/10.3389/fmicb.2016.02138
  • Elliott B, Androga GA, Knight DR, Riley TV. Clostridium difficile infection: evolution, phylogeny and molecular epidemiology. Infect Genet Evol 49:1-11. http://dx.doi.org/10.1016/j.meegid.2016.12.018

2016

  • Moono P, Foster NF, Hampson DJ, Knight DR, Bloomfield LE, Riley TV. Clostridium difficile Infection in Production Animals and Avian Species: A Review. Foodborne Pathog Dis 13:647-655. http://dx.doi.org/10.1089/fpd.2016.2181
  • McGovern AM, Foster NF, Pereira AL, Knight DR, Elliott B, Chang BJ, Riley TV. Human Clostridium difficileinfection caused by a livestock-associated PCR ribotype 237 strain in Western Australia. J Med Microbiol Case Rep 3. http://dx.doi.org/10.1099/jmmcr.0.005062
  • Knight DR, Androga GA, Ballard SA, Howden BP, Riley TV. A phenotypically silent vanB2 operon carried on a Tn1549-like element in Clostridium difficilemSphere 1: e00177-16. http://dx.doi.org/10.1128/mSphere.00177-16
  • Knight DR and Riley TV. Clostridium difficile clade 5 in Australia: antimicrobial susceptibility profiling of PCR ribotypes of human and animal origin. J Antimicrob Chemother 71: 2213-2217. http://dx.doi.org/10.1093/jac/dkw124
  • Knight DR, Putsathit P, Elliott B, Riley TV. Contamination of Australian newborn calf carcasses at slaughter with Clostridium difficileClin Microbiol Infect 22: 266.e1–266.e7. http://dx.doi.org/10.1016/j.cmi.2015.11.017

2015

  • Moono P, Putsathit P, Knight DR, Squire MM, Hampson DJ, Foster NF, Riley TV. Persistence of Clostridium difficile RT 237 infection in a Western Australian piggery. Anaerobe 37: 62-66. http://dx.doi.org/10.1016/j.anaerobe.2015.11.012
  • Squire MM, Knight DR, Riley TV. Community-acquired Clostridium difficile infection and Australian food animals. Microbiol Aust 36(3). http://dx.doi.org/10.1071/MA15040
  • Knight DR, Giglio S, Huntington PG, Korman TM, Kotsanas D, Moore CV, Paterson DL, Prendergast L, Huber CA, Robson J, Waring L, Wehrhahn MC, Weldhagen GF, Wilson RM, Riley TV. Surveillance for antimicrobial resistance in Australian isolates of Clostridium difficile, 2013-2014. J Antimicrob Chemother 70: 2992-9. http://dx.doi.org/10.1093/jac/dkv220
  • Knight DR, Hart J, Gottardo NG, Eyre DW, Crook DW, Riley TV. Two cases of Clostridium difficile infection in unrelated oncology patients attributable to a single clone of C. difficile PCR ribotype 126. J Med Microbiol Case Rep 2. http://dx.doi.org/10.1099/jmmcr.0.000043
  • Knight DR, Elliott B, Chang B, Perkins TT, Riley TV. Diversity and evolution in the genome of Clostridium difficileClin Microbiol Rev 28: 721-741. http://dx.doi.org/10.1128/CMR.00127-14
  • Grandgirard D, Furi L, Ciusa ML, Baldassarri L, Knight DR, Morrissey I, Largiadèr CR, Leib SL, Oggioni MR. Mutations upstream of fabI in triclosan-resistant Staphylococcus aureus strains are associated with elevated fabI gene expression. BMC Genomics 16:345. http://dx.doi.org/10.1186/s12864-015-1544-y
  • Oggioni MR, Coelho JR, Furi L, Knight DR, Viti C, Orefici G, Martinez JL, Freitas AT, Coque T, Morrissey I. Significant differences characterize the correlation coefficients between biocide and antibiotic susceptibility profiles in Staphylococcus aureus. Curr Pharm Des 21: 2054-7. http://dx.doi.org/10.2174/1381612821666150310103238

2014

  • Knight DR, Squire MM, Riley TV. Nationwide surveillance study of Clostridium difficile in Australian neonatal pigs shows high prevalence and heterogeneity of PCR ribotypes. Appl Environ Microbiol 81: 119-123. http://dx.doi.org/10.1128/AEM.03032-14
  • Knight DR, Squire MM, Riley TV. Laboratory detection of Clostridium difficile in piglets in Australia. J Clin Microbiol 52: 3856-62. http://dx.doi.org/10.1128/JCM.01225-14
  • Hart J, Putsathit P, Knight DR, Sammels L, Riley TV, Keil A. Clostridium difficile infection diagnosis in a paediatric population: comparison of methodologies. Eur J Clin Microbiol Infect Dis 33: 1555-64. http://dx.doi.org/10.1007/s10096-014-2108-9
  • Morrissey I, Oggioni MR, Knight DR, Curiao T, Coque T, Kalkanci A, Martinez JL. 2014. Evaluation of epidemiological cut-off values indicates that biocide resistant subpopulations are uncommon in natural isolates of clinically-relevant microorganisms. PLoS One 9: e86669. http://dx.doi.org/10.1371/journal.pone.0086669

2013

  • Friedman ND, Pollard J, Stuart D, Alfredson D, Knight DR, Davey E, Parry L, Riley TV. Prevalence of Clostridium difficile colonization among healthcare workers. BMC Infect Dis 13:459. http://dx.doi.org/10.1186/1471-2334-13-459
  • Knight DR and Riley TV. Prevalence of Clostridium difficile gastrointestinal carriage in Australian sheep and lambs. Appl Environ Microbiol 79:5689-92. http://dx.doi.org/10.1128/AEM.01888-13
  • Furi L, Ciusa ML, Knight DR, Di Lorenzo V, Tocci N, Cirasola D, Aragones L, Coelho JR, Freitas AT, Marchi E, Moce L, Visa P, Northwood JB, Viti C, Borghi E, Orefici G, Morrissey I, Oggioni MR. Evaluation of reduced susceptibility to quaternary ammonium compounds & bisbiguanides in clinical isolates and laboratory-generated mutants of Staphylococcus aureusAntimicrob Agents Chemother 57:3488-3497. http://dx.doi.org/10.1128/AAC.00498-13
  • Knight DR, Thean S, Putsathit P, Fenwick S, Riley TV. Cross-sectional study reveals high prevalence of C. difficile non-PCR ribotype 078 strains in Australian veal calves at slaughter. Appl Environ Microbiol 79:2630-5. http://dx.doi.org/10.1128/AEM.03951-12

2012

  • Morrissey I, Seifert H, Canton R, Nordmann P, Stefani S, MacGowan A, Janes R, Knight DR. Activity of oritavancin against methicillin-resistant staphylococci, vancomycin-resistant enterococci, and b-haemolytic streptococci collected from western European countries in 2011. J Antimicrob Chemother 68:164-167. http://dx.doi.org/10.1093/jac/dks344
  • Cuisa ML, Furi LKnight DR, Decorosi F, Fondi M, Raggi C, Coelho JR, Aragones L, Moce L, Visa P, Freitas AT, Baldassarri L, Renato F, Viti C, Orefici G, Martinez JL, Morrissey I, Oggioni MR. A novel resistance mechanism to triclosan witnesses horizontal gene transfer and demonstrates selective pressure for reduced biocide susceptibility in clinical strains of S. aureusInt J Antimicrob Agents 40:210-220. †Authors contributed equally to this work. http://dx.doi.org/10.1016/j.ijantimicag.2012.04.021
  • Coelho JR, Carriço JA, Knight DR, Martinez J, Morrissey I, Oggioni MR, Freitas AT. The use of machine learning methodologies to analyze antibiotic and biocide susceptibility in S. aureusPLoS One 8:e55582. http://dx.doi.org/10.1371/journal.pone.0055582

2005

  • Huber PA, Birdsey GM, Lumb MJ, Prowse DT, Perkins TJ, Knight DR and Danpure CJ. Peroxisomal import of human alanine: glyoxylate aminotransferase (AGT) requires ancillary targeting information remote from its C-terminus. J Biol Chem 280:27111-20. http://dx.doi.org/10.1074/jbc.M502719200

 

 

Engagement

Invited talks at national and international scientific meetings

  • Knight DR. 09/2021. New evolutionary and ecological insights into the C. difficile species. 12th Intl Conference on the Molecular Biology & Pathogenesis of the Clostridia. Banff, Canada (Virtual). 
  • Knight DR. 06/2021. The Clostridium difficile species problem: new taxonomic insights into an important One Health pathogen. The inaugural World Microbe Forum co-hosted by the American Society for Microbiology & Federation of European Microbiological Societies). USA-based, Virtual.
  • Knight DR. 06/2021. Award Plenary Lecture: The Clostridium difficile species problem. 48th Annual Scientific Meeting of the Australian Society for Microbiology. Melbourne, Australia.
  • Knight DR. 04/2019. New evidence for a zoonotic potential of C. difficile. 29th Annual Congress of the European Society of Clinical Microbiology and Infectious Diseases. Amsterdam, Netherlands. 
  • Knight DR. 09/2018. One Health: the optimal paradigm for studying evolution and transmission in
    C. difficile.
    6th International Clostridium difficile Symposium. Bled, Slovenia.
  • Knight DR. 07/2018. C. difficile Infection in Australia: not so nosocomial anymore. 46th Annual Scientific Meeting of the Australian Society for Microbiology. Brisbane, Australia.          

 

 

Roles and responsibilities

Doctoral and Masters supervisions

Ms Stacey Hong; PhD (2014-2020, completed), University of Western Australia.

  • Molecular epidemiology of emerging C. difficile RT251 in Australia.

Dr Korakrit Imwattana; PhD (2019-2021, submitted), University of Western Australia.

  • Phylogenetics and clinical epidemiology of global epidemic C. difficile RT017.

Ms Karla Cautivo; PhD (2019-), Murdoch University.

  • Evolution of C. difficile in native fauna and soils in Western Australia.

Ms Natasza Hain-Saunders; PhD (2020-), Murdoch University.

  • Molecular epidemiology of Clostridium difficile Infection in equine populations in Australia.

Ms Keeley O’Grady; MSc (2019-), Murdoch University.

  • Genomic epidemiology and antimicrobial resistance in C. difficile.

 

 

Community engagement

Editorial Activities

  • Associate Editor, Anaerobe (2021-2024)
  • Invited Editorial Board Member, Anaerobe (2021-)
  • Invited Editorial Board Member, Epidemiology and Infection (2019-2021)

  

Australian Society for Microbiology (ASM)

  • Member (MASM) since 2012
  • Committee member (WA branch) since 2013.
  • Current role: Treasurer (2019-)
  • Previous roles: Communications (2013-16), Awards and scholarships (2017-18), Scientific program (2018-19)

 

Local Organising Committees (LOCs)

  • Secretary, ASM national scientific meeting 2016 (Perth, WA)
  • Founding member and scientific program convener, West Coast Microbiome Network (WCMN) symposiums 2016, 2017, 2018. 2019, 2021 (Perth, WA)
  • BacPath 15, The Molecular Biology of Bacterial Pathogens 2019 (Perth, WA)

 

 

Teaching overview

Murdoch University

  • Invited lecturer, Molecular epidemiology of C. difficile: BMS315 Advances in Medical Science

 

University of Western Australia

  • Invited lecturer, Antimicrobial resistance: MICR5814 Epidemiology and Infection, MICR5829 Foundations of Infectious Disease, DENT4202 Immunology, Pathology and Periodontics

 

 

Education/Academic qualification

Microbiology, PhD, School of Biomedical Sciences

20132018

Award Date: 31 Mar 2018

External positions

NHMRC Fellow, Murdoch University

20182021

Research expertise keywords

  • Microbial genomics
  • Surveillance
  • Pathogens
  • AMR
  • Evolution
  • Phylogenetics
  • Pathogenicity
  • One Health

Fingerprint

Dive into the research topics where Dan Knight is active. These topic labels come from the works of this person. Together they form a unique fingerprint.
  • 1 Similar Profiles

Network

Recent external collaboration on country/territory level. Dive into details by clicking on the dots or